Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of VLA.PA is 7.1 and suggests 52% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell